Coherus Oncology, Inc. 8-K

What Happened
Coherus Oncology, Inc. filed an 8-K on January 13, 2026 (Item 2.02) to disclose preliminary unaudited net revenues for the quarter and fiscal year ended December 31, 2025, and its cash, cash equivalents and investments as of that date. The company provided these figures as part of a presentation at the 43rd Annual J.P. Morgan Healthcare Conference; the slide with the preliminary financial information is furnished as Exhibit 99.1 to the filing.

Key Details

• Filing date: January 13, 2026 (Form 8‑K, Item 2.02).
• Event: Preliminary unaudited net revenues for the quarter and fiscal year ended December 31, 2025 were disclosed.
• Liquidity snapshot: Cash, cash equivalents and investments as of December 31, 2025 were included.
• Presentation: Information was furnished via a slide (Exhibit 99.1) shown at the J.P. Morgan Healthcare Conference; the report is signed by CEO Dennis M. Lanfear.

Why It Matters
This 8‑K gives investors an updated view of Coherus’ recent revenue performance and year-end liquidity ahead of audited results — useful for assessing near-term financial health and runway. Because the figures are preliminary and unaudited, they may be adjusted in the company’s final financial statements. The disclosure at a major investor conference also indicates management is actively communicating results to the market.